CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

A Pilot Study of CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

This is a pilot and feasibility study of transplant eligible, higher risk myelodysplastic syndrome (MDS) patients to determine the safety and tolerability of a lower -dose and higher-dose CPX-351 regimen, with secondary objectives including complete remission (CR) rates and proportion of patients proceeding to transplant.

Study Overview

• Status: Active, not recruiting
• Conditions: Myelodysplastic Syndromes
• Intervention / Treatment: Drug: CPX-351; Procedure: Research skin biopsy; Procedure: Research blood draw; Procedure: Research bone marrow aspirate

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Tampa, Florida, United States, 33612
      • Moffitt Cancer Center
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine
  • Washington
    • Seattle, Washington, United States, 98109
      • Fred Hutchinson Cancer Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of myelodysplastic syndrome (MDS) with an IPSS-R score of Intermediate, High or Very High (see Appendix A) AND ≥ 5% myeloblasts in the bone marrow.
• Age 18-70 years.
• ECOG performance status ≤ 2 (see Appendix B)

Adequate renal and hepatic function as defined below:

*Total bilirubin ≤ 2.0 x IULN*

• AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
• Serum creatinine ≤ 2.0 mg/dL

• Note: If, in the opinition of the treatment physician, the bilirubin is elevated secondary to hemolysis or Gilbert's disease, the patient may be eligible after discussion with the Washington University PI.

  • Left ventricular cardiac ejection fraction ≥ 50% by echocardiography or MUGA.
  • Deemed by the treating physician to be a suitable candidate for cytotoxic induction therapy and an alloHCT candidate at the time of enrollment.
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and continuing until 30 days after the last study treatment.
  • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• Prior treatment for MDS with disease-modifying therapy (conventional or investigational) (i.e. hypomethylator therapy, lenalidomide, or prior AML-like induction therapy intended for the therapy of MDS). Use of prior growth factor and ESA support is permitted.
• Currently receiving any other investigational agents.
• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to CPX-351 or other agents used in the study.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
• History of Wilson's disease or other copper-metabolism disorder.
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
• Known active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible. Patients who are seropositive for HCV but have a negative viral load are also eligible provided that the patient has completed a course of therapy for HCV.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: CPX-351; CPX-351 will be given according to the assigned dose level over a minimum of a 90-minutes via IV infusion on Days 1, 3, and 5 of the first induction; If the treating physician elects to perform a day 14 bone marrow biopsy then, a second induction may be considered for patients in the absence of a chemoablated, hypocellular marrow on the Day 14 bone marrow assessment, if the patient has failed to achieve a marrow CR, and it is deemed safe to administer by the treating physician. The second induction uses a modified schedule in which CPX-351 will be given according to the assigned dose level on Days 1 and 3; In the absence of disease progression or unacceptable toxicity, the patient may continue to consolidation at the discretion of the treating physician or the patient may proceed to alloHCT after induction at the discretion of the treating physician

Drug: CPX-351; -CPX-351 will be provided by Jazz Pharmaceuticals; Other Names: Daunorubicin and cytarabine; Vyxeos™; Procedure: Research skin biopsy; -And/or buccal swab; Pre-treatment; Post-induction (no earlier than Day 28 and no later than Day 56 from last induction); Procedure: Research blood draw; Pre-treatment; Post-induction (no earlier than Day 28 and no later than Day 56 from last induction); Post-consolidation 1 (if applicable); Post-consolidation 2 (if applicable); Post-transplant Day 30 (if applicable); Post-transplant Day 100 (if applicable); Procedure: Research bone marrow aspirate; Pre-treatment; Post-induction (no earlier than Day 28 and no later than Day 56 from last induction); Post-consolidation 1 (if applicable); Post-consolidation 2 (if applicable); Post-transplant Day 30 (if applicable); Post-transplant Day 100 (if applicable)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety and tolerability of a CPX-351 regimen in a transplant eligible, higher risk MDS population as measured by the proportion of participants who experience an adverse event by patient, type of event, and grade of event	Through 56 days after the last dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate in MDS patients treated with CPX-351	Overall response rate = complete remission + marrow complete remission + partial response + hematologic improvement; Patients will be assessed for response according to modified International Working Group (IWG) criteria for MDS	56 days after the last dose
Best overall response in MDS patients treated with CPX-351	-Patients will be assessed for response according to modified International Working Group (IWG) criteria for MDS	56 days after the last dose
Remission duration in MDS patients treated with CPX-351	Defined as the interval from the date complete remission is documented to the date of recurrence. This is determined only for patients achieving a complete remission.; Patients will be assessed for response according to modified International Working Group (IWG) criteria for MDS	Through 5 years
Relapse-free survival in MDS patients treated with CPX-351	-Patients will be assessed for response according to modified International Working Group (IWG) criteria for MDS	Through 5 years
Progression-free survival in MDS patients treated with CPX-351	Defined as the interval from the date of first dose of study drug to disease progression or death from MDS.; Patients will be assessed for response according to modified International Working Group (IWG) criteria for MDS	Through 5 years
Overall survival in MDS patients treated with CPX-351	-Defined as the date of first dose of study drug to the date of death from any cause.	Through 5 years
Complete remission + marrow complete remission rates in patients treated with CPX-351	-Patients will be assessed for response according to modified International Working Group (IWG) criteria for MDS	56 days after the last dose
Post-induction mortality in MDS patients treated with CPX-351	-Rate of death	Day 30
Post-induction mortality in MDS patients treated with CPX-351	-Rate of death	Day 60
Safety and feasibility of CPX-351 consolidation therapy in MDS patients as measured by the proportion of patients who experience an adverse event by patient, type of event, and grade of event		Through 56 days after the last dose
Proportion of MDS patients treated with CPX-351 proceeding to allogeneic hematopoietic cell transplant		Through 56 days after the last dose
Overall survival in MDS patients treated with CPX-351 in patients undergoing allogeneic hematopoietic cell transplant	-Defined as the date of first dose of study drug to the date of death from any cause.	Day 100
Overall survival in MDS patients treated with CPX-351 in patients undergoing allogeneic hematopoietic cell transplant	-Defined as the date of first dose of study drug to the date of death from any cause.	1 year
Non-relapse mortality in MDS patients treated with CPX-351 in patients undergoing allogeneic hematopoietic cell transplant		Day 100
Non-relapse mortality in MDS patients treated with CPX-351 in patients undergoing allogeneic hematopoietic cell transplant		1 year
Event-free survival in MDS patients treated with CPX-351 in patients undergoing allogeneic hematopoietic cell transplant	Defined as the interval from the date of first dose of study drug to date of treatment failure, recurrence, or death due to any cause.; Patients will be assessed for response according to modified International Working Group (IWG) criteria for MDS	Day 100
Event-free survival in MDS patients treated with CPX-351 in patients undergoing allogeneic hematopoietic cell transplant	Defined as the interval from the date of first dose of study drug to date of treatment failure, recurrence, or death due to any cause.; Patients will be assessed for response according to modified International Working Group (IWG) criteria for MDS	1 year

Collaborators and Investigators

• Sponsor: Washington University School of Medicine
• Collaborators: Jazz Pharmaceuticals
• Investigators: Principal Investigator: Meagan Jacoby, M.D., Ph.D., Washington University School of Medicine

Publications and helpful links

Helpful Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): December 14, 2018
• Primary Completion (Actual): November 27, 2021
• Study Completion (Estimated): March 25, 2027

Study Registration Dates

• First Submitted: June 18, 2018
• First Submitted That Met QC Criteria: June 18, 2018
• First Posted (Actual): June 28, 2018

Study Record Updates

• Last Update Posted (Actual): April 9, 2024
• Last Update Submitted That Met QC Criteria: April 6, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Disease; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Syndrome; Myelodysplastic Syndromes; Preleukemia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin
• Other Study ID Numbers: 201807148

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No